Chester County News and Community Website
WILMINGTON, DE — A new study from ChristianaCare’s Gene Editing Institute shows that disabling a single gene with CRISPR technology can restore chemotherapy sensitivity in lung cancer, a development researchers …
CRISPR Breakthrough Revives Chemo Response in Resistant Lung Tumors, Study Finds Read More
HARRISBURG, PA — A new report from the American Lung Association paints a mixed picture for Pennsylvania’s fight against lung cancer. While the state ranks among the best in the …
Pennsylvania Among Top States for Lung Cancer Survival, But Risks Remain High Read More
PLYMOUTH MEETING, PA — New research published online in JNCCN—Journal of the National Comprehensive Cancer Network finds that people with cancer who quit smoking had a much lower risk of …
Quitting Smoking After Cancer Diagnosis Tied to Sharply Lower Two-Year Mortality, Study Finds Read More
NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients with non-small …
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations Read More
WILMINGTON, DE — AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, delivered a statistically significant and clinically meaningful improvement in overall survival for patients …
AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial evaluating firmonertinib as a first-line treatment …
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded two new research grants to support studies on zipalertinib, a promising therapy for Non-Small …
NCCN Awards Grants to Advance Innovative Lung Cancer Research on Zipalertinib Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated …
FDA Grants Accelerated Approval for DATROWAY in Advanced EGFR-Mutated Lung Cancer Read More
HARRISBURG, PA — The American Lung Association in Pennsylvania is leading the charge against lung cancer this week, turning major landmarks turquoise as part of Turquoise Takeover and Lung Cancer …
Pennsylvania Goes Turquoise for Lung Cancer Awareness Read More WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages for epidermal growth …
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025 Read More